CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of myelofibrosis.
  
  LEARNING OBJECTIVES

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF regarding their long-term prognosis.
  • Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for primary and secondary MF.
  • Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for patients with MF.
  • Review available research data with and the current clinical role of next-generation JAK inhibitors for patients with MF and severe thrombocytopenia.
  • Evaluate published research findings with the use of JAK inhibitors for patients with MF and anemia to optimize decision-making for this population.
  • Assess available research findings with novel therapies and combination regimens incorporating JAK inhibitors, and consider the potential clinical application of these approaches.
  • Increase participation in active research protocols by counseling appropriately selected patients regarding the biological rationale for and available efficacy and safety data with novel investigational agents and strategies for MF.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.75 (audio) and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHMF24/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASHMF24/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHMF24/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASHMF24.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Prithviraj Bose, MD
  Professor, Department of Leukemia
  Co-Leader, Section of Myeloproliferative Neoplasms
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committees: Blueprint Medicines, Geron Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, GSK, Incyte Corporation, Ionis Pharmaceuticals Inc, Jubilant Pharma Limited, Keros Therapeutics, Morphic Therapeutic, MorphoSys, Novartis, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Geron Corporation, Incyte Corporation, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Sumitomo Dainippon Pharma Oncology Inc, Telios Pharma Inc.
  
  Angela G Fleischman, MD, PhD
  Associate Professor
  Department of Medicine, Division of Hematology/Oncology
  UC Irvine Health
  Irvine, California
  
  Advisory Committees: CTI BioPharma, a Sobi Company, Incyte Corporation; Consulting Agreements: Ionis Pharmaceuticals Inc; Speakers Bureaus: CTI BioPharma, a Sobi Company, GSK, PharmaEssentia.
  
  Abdulraheem Yacoub, MD
  Professor of Medicine
  Division of Hematologic Malignancies and Cellular Therapeutics (HMCT)
  Department of Internal Medicine
  The University of Kansas Cancer Center
  Westwood, Kansas
  
  Consulting Agreements: AbbVie Inc, Acceleron Pharma, Apellis, CTI BioPharma, a Sobi Company, Gilead Sciences Inc, Incyte Corporation, Karyopharm Therapeutics, Notable Labs, Novartis, Pfizer Inc, PharmaEssentia, Protagonist Therapeutics, Servier Pharmaceuticals LLC.
  
  MODERATOR
  Andrew T Kuykendall, MD
  Associate Member, Department of Malignant Hematology
  Moffitt Cancer Center
  Associate Professor, Department of Oncologic Sciences
  University of South Florida
  Tampa, Florida
  
  Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, Janssen Biotech Inc, Protagonist Therapeutics, MorphoSys; Data and Safety Monitoring Boards/Committees: Geron Corporation.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from CTI BioPharma, a Sobi Company, Geron Corporation, GSK, Incyte Corporation, and Karyopharm Therapeutics.
  
  Release date: January 2025
  Expiration date: January 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.